Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of PatIents with treatment ResIstant hyperTension study.


Journal

Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 16 8 2019
medline: 7 7 2020
entrez: 16 8 2019
Statut: ppublish

Résumé

We evaluated the characteristics of patients with treatment-resistant hypertension (TRH) and the prevalence of TRH in a large multicountry sample of specialist tertiary centres. The Survey of PatIents with treatment ResIstant hyperTension (SPIRIT) study was a retrospective review of medical records of patients seen at tertiary centres located in Western Europe, Eastern Europe, North America, South America, Australia and Asia. Data on demographics, medical history and medication use were extracted from medical records. Prevalence and incidence of TRH were based upon estimated catchment populations. On thousand, five hundred and fifty-five patients from 76 centres were included, mostly from centres that specialize in hypertension (55%), cardiology (11%) or nephrology (19%). Mean age was 64, 60% were men, 62% were Caucasian, 36% had chronic kidney disease, 41% had diabetes, 12% were smokers and 31% had a previous cardiovascular event. Daytime and night-time ambulatory blood pressure (BP) was the most frequently used measurement for diagnosis (82%). Ninety-five percent of patients were prescribed diuretics, 93% an inhibitor of the renin-angiotensin system, 86% a calcium channel blocker, 74% a beta-blocker and 36% an aldosterone antagonist. The overall estimated mean incidence of TRH was 5.8 per 100 000 per year (ranging between 2.3 and 14.0 across regions) and the corresponding estimated mean prevalence of TRH was 23.9 per 100 000 (ranging between 7.6 and 90.5 across regions). Observed variation likely reflects real differences in patient characteristics and physician management practices across regions and specialities but may also reflect differences in patient selection and errors in estimation of catchment population across participating centres.

Identifiants

pubmed: 31415307
doi: 10.1097/HJH.0000000000002184
doi:

Substances chimiques

Adrenergic beta-Antagonists 0
Antihypertensive Agents 0
Calcium Channel Blockers 0
Diuretics 0
Mineralocorticoid Receptor Antagonists 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2216-2224

Auteurs

Cheryl Carcel (C)

The George Institute for Global Health, University of New South Wales.
The University of Sydney, Sydney Medical School.
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Bruce Neal (B)

The George Institute for Global Health, University of New South Wales.
The University of Sydney, Sydney Medical School.
Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom.

Suzanne Oparil (S)

Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

Kris Rogers (K)

The George Institute for Global Health, University of New South Wales.

Krzysztof Narkiewicz (K)

Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland.

Ji Guang Wang (JG)

Shanghai Key Laboratory of Hypertension, Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Ernesto L Schiffrin (EL)

Lady Davis Institute and Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Neil Poulter (N)

Imperial Clinical Trials Unit, Imperial College London, London, UK.

Michel Azizi (M)

University Paris Descartes.
Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit.
Institut national de la santé et de la recherche médicale, Centre d'Investigation Clinique, Paris, France.

John Chalmers (J)

The George Institute for Global Health, University of New South Wales.
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH